SEC Form 4 · accession 0001437749-26-021000
Eton Pharmaceuticals, Inc. · ETON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer McKie Adams
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 17, 2026 · 5:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001710340
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 17, 2026 | M | 50,000 | $3.78 | A | 50,000 | D | |
| Common StockF1,F3 | Jun 17, 2026 | S | 50,000 | $32.4759 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock OptionF2 | $3.78 | Jun 17, 2026 | M | 50,000 | D | Feb 7, 2023 | Feb 6, 2032 | Common Stock | 50,000 | 0 | D |
Explanation of responses
- F1The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested on February 7, 2023.
- F3The shares were sold in multiple trades at prices ranging from $32.10 to $32.71. The price reported above reflects the weighted average sales price.
Remarks
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.